Gary E Schiltz
Overview
Explore the profile of Gary E Schiltz including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
44
Citations
960
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Vagadia P, Izquierdo-Ferrer J, Mazewski C, Blyth G, Beauchamp E, Clutter M, et al.
J Med Chem
. 2025 Mar;
68(5):5824-5844.
PMID: 40033556
MNK activity is regulated by the p38 and Erk MAPK pathways. Phosphorylation of MNK leads to its activation and binding to the eIF4G/eIF4E complex. MNK then phosphorylates eIF4E at Ser209,...
2.
Monsen P, Bommi P, Grigorescu A, Lauing K, Mao Y, Berardi P, et al.
J Med Chem
. 2025 Feb;
68(4):4961-4987.
PMID: 39946350
Indoleamine 2,3-dioxygenase 1 (IDO1) is an immunosuppressive protein that inhibits antitumor immunity through both tryptophan metabolism and nonenzymatic functions. Drugs targeting IDO1 enzyme activity have failed to improve the overall...
3.
Monsen P, Bommi P, Grigorescu A, Lauing K, Mao Y, Berardi P, et al.
bioRxiv
. 2025 Jan;
PMID: 39829781
Indoleamine 2,3-dioxygenase 1 (IDO1) is a potently immunosuppressive protein that inhibits antitumor immunity through both tryptophan metabolism and non-enzymatic functions. Pharmacological therapies targeting IDO1 enzyme activity have generally failed to...
4.
Qiao F, Binkowski T, Broughan I, Chen W, Natarajan A, Schiltz G, et al.
Cancers (Basel)
. 2024 Sep;
16(18).
PMID: 39335149
Drug discovery historically starts with an established function, either that of compounds or proteins. This can hamper discovery of novel therapeutics. As structure determines function, we hypothesized that unique 3D...
5.
Shields B, Yan H, Lim S, Burwell S, Cammarata C, Fleming E, et al.
Nat Methods
. 2024 Jun;
21(7):1288-1297.
PMID: 38877316
Precision pharmacology aims to manipulate specific cellular interactions within complex tissues. In this pursuit, we introduce DART.2 (drug acutely restricted by tethering), a second-generation cell-specific pharmacology technology. The core advance...
6.
Qiao F, Binknowski T, Broughan I, Chen W, Natarajan A, Schiltz G, et al.
bioRxiv
. 2024 Jun;
PMID: 38826221
Drug discovery starts with known function, either of a compound or a protein, in-turn prompting investigations to probe 3D structure of the compound-protein interface. As protein structure determines function, we...
7.
Rabin E, Huang J, Kim M, Mozny A, Lauing K, Penco-Campillo M, et al.
Brain Behav Immun Health
. 2024 Apr;
38:100753.
PMID: 38600951
Background: Increased age is a strong and unfavorable prognostic factor for patients with glioblastoma (GBM). However, the relationships between stratified patient age, comorbidities, and medications have yet to be explored...
8.
Johnson M, Bell A, Lauing K, Ladomersky E, Zhai L, Penco-Campillo M, et al.
Clin Cancer Res
. 2023 Sep;
29(23):4973-4989.
PMID: 37725593
Purpose: Glioblastoma (GBM) is the most common aggressive primary malignant brain tumor in adults with a median age of onset of 68 to 70 years old. Although advanced age is...
9.
Valdivia A, Vagadia P, Guo G, OBrien E, Matei D, Schiltz G
J Med Chem
. 2023 Jul;
66(14):9445-9465.
PMID: 37449845
Tissue transglutaminase (TG2) is a multifunctional enzyme involved in the cross-linking of extracellular matrix proteins, formation of complexes with fibronectin (FN) and integrins, and GTP hydrolysis. TG2 is activated in...
10.
Dahl R, Moore A, Knight C, Mauger C, Zhang H, Schiltz G, et al.
Int J Mol Sci
. 2023 Jul;
24(13).
PMID: 37446234
Alzheimer's disease (AD) is an irreversible neurodegenerative disease that affects millions of people worldwide. AD does not have a cure and most drug development efforts in the AD field have...